Parkinson's Patch Nears U.S. Approval
Once-a-Day Drug for Parkinson's Disease Safe, Effective in Clinical Trials
WebMD News Archive
Can Parkinson's Patch Outperform Its Peers? continued...
Parkinson's expert Curt R. Freed, MD, heads the division of clinical
pharmacology and toxicology at the University of Colorado Health Science Center
in Denver. In an email interview, Freed says that it's by no means sure that
the patch will eliminate the "off" periods seen with L-dopa and oral
"The other dopamine agonists have half-lives in the six-hour range,
which is nearly as good as continuous administration," Freed tells WebMD.
"Patients with advanced Parkinson’s disease may have only two clinical
states, immobile 'off' and [involuntary movement] 'on.' Whether rotigotine by
patch will change this scenario remains to be seen."
U.S. Approval Expected
Schwarz Pharma Product Director Michael Davis tells WebMD that the FDA has
given the Parkinson's patch an "approvable letter." Such letters
usually mean that the agency thinks it has enough information to approve the
Davis says the company hopes to hear good news from the FDA in the first
half of 2007.
So who will use the drug? Freed says that won't be known until doctors have
a chance to see what the drug can do in widespread clinical use.
Watts says that the patch is very likely to be helpful "for an important
subset of patients."
"As with any new development and any new treatment for Parkinson's
disease, the patch expands the options for patients," Watts says. "This
is an important step in the treatment of Parkinson's disease. But there are
also many other lines of investigation that will lead to new